The U.S. Food and Drug Administration (FDA) has approved trospium chloride tablets (Sanctura™, Pliva) for the treatment of overactive bladder. Symptoms include urge urinary incontinence, urgency, and urinary frequency.
As a quaternary ammonium compound, this agent belongs to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or unstable detrusor muscle function is believed to be the cause of overactive bladder. Sanctura™ is currently marketed as a prescription drug in Europe. canadian discount drugs
Patients with urinary or gastric retention, uncontrolled narrow-angle glaucoma, or hypersensitivity to the product should not use it.
Sanctura™ is scheduled to be available for sale in the U.S. in late 2004.
